[{"orgOrder":0,"company":"Aurobindo Pharma Limited","sponsor":"Evive Biotech","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"INDIA","productType":"Protein","year":"2022","type":"Licensing Agreement","leadProduct":"Benegrastim","moa":"G-CSF receptor","graph1":"Hematology","graph2":"Phase III","graph3":"Aurobindo Pharma Limited","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Aurobindo Pharma Limited \/ Evive Biotech","highestDevelopmentStatusID":"10","companyTruncated":"Aurobindo Pharma Limited \/ Evive Biotech"}]

Find Hematology Drugs in Phase III Clinical Development in INDIA

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : Under the terms of the agreement, Evive will be responsible for the ongoing development, manufacturing, registration, and supply of Ryzneuta (benegrastim), while Acrotech will use its sales and commercialisation capabilities to market and distribute the ...

                          Product Name : Ryzneuta

                          Product Type : Protein

                          Upfront Cash : Undisclosed

                          November 23, 2022

                          Lead Product(s) : Benegrastim

                          Therapeutic Area : Hematology

                          Highest Development Status : Phase III

                          Sponsor : Evive Biotech

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          02

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : Under the terms and conditions of the agreement, CMS will be responsible for development, registration and commercialisation of Desidustat in Greater China.

                          Product Name : Oxemia

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          January 20, 2020

                          Lead Product(s) : Desidustat

                          Therapeutic Area : Hematology

                          Highest Development Status : Phase III

                          Sponsor : China Medical System Holdings Limited

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank